Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) dropped 5.2% during trading on Thursday . The company traded as low as $3.06 and last traded at $3.10, with a volume of 101,524 shares traded. The stock had previously closed at $3.27.

A number of brokerages recently issued reports on AUPH. Zacks Investment Research lowered Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, May 5th. Canaccord Genuity reissued a “buy” rating on shares of Aurinia Pharmaceuticals in a research report on Thursday, May 12th. HC Wainwright began coverage on Aurinia Pharmaceuticals in a research report on Thursday, June 30th. They issued a “buy” rating and a $7.00 target price on the stock. Finally, Leerink Swann reissued an “outperform” rating and issued a $7.00 target price on shares of Aurinia Pharmaceuticals in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $7.15.

The firm’s 50-day moving average price is $2.71 and its 200-day moving average price is $2.59. The company’s market capitalization is $99.76 million.

Aurinia Pharmaceuticals Inc (Aurinia) is a Canada-based is a clinical stage pharmaceutical company. The Company is focused on the development of its therapeutic immunomodulating drug candidate, voclosporin, which is a calcineurin inhibitor (CNI). Voclosporin is an oral drug, administered twice daily.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.